CLDN4 and breast carcinoma: The survival time of the Claudin-4 high-expression group was significantly lower than that of the low-expression group, and a multivariate COX regression model was established to find that high expression of Claudin-4 was an independent factor affecting the poor prognosis of breast cancer.